CLOVIS ONCOLOGY Forum: Community User: Maroni

Kommentare 2.548
V
VanHalen, 02.03.2016 23:50 Uhr
0
JPMorgan Chase & Co. reiterated their buy rating on shares of Clovis Oncology Inc (NASDAQ:CLVS)in a research note released on Friday morning,Analyst Ratings.Net reports. The brokerage currently has a $42.00 price objective on the biopharmaceutical company’s stock.
V
VanHalen, 02.03.2016 23:17 Uhr
0
Naja Bericht vom Montag.. Lächerlich xD Die anderen Werten mit Buy und 40 USD
C
COLOGNE79, 02.03.2016 22:59 Uhr
0
Clovis Oncology Inc (NASDAQ:CLVS) had its price target decreased by Goldman Sachs from $23.00 to $19.00 in a report published on Monday,StockTargetPrices.com reports. Shares of Clovis Oncology (NASDAQ:CLVS) opened at 18.00 on Monday. Clovis Oncology has a 12 month low of $17.17 and a 12 month high of $116.75. The firm’s market capitalization is $689.76 million. The stock has a 50 day moving average price of $22.47 and a 200 day moving average price of $60.48. A number of hedge funds and institutional investors recently added to or reduced their stakes in CLVS. Vident Investment Advisory LLC boosted its position in Clovis Oncology by 55.2% in the fourth quarter. Vident Investment Advisory LLC now owns 42,347 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 15,062 shares in the last quarter. Credit Suisse AG boosted its position in Clovis Oncology by 19.3% in the fourth quarter. Credit Suisse AG now owns 125,000 shares of the biopharmaceutical company’s stock valued at $4,375,000 after buying an additional 20,219 shares in the last quarter. Redmile Group LLC boosted its position in Clovis Oncology by 87.5% in the fourth quarter. Redmile Group LLC now owns 1,795,936 shares of the biopharmaceutical company’s stock valued at $62,858,000 after buying an additional 838,302 shares in the last quarter. Palo Alto Investors LLC boosted its position in Clovis Oncology by 14.1% in the fourth quarter. Palo Alto Investors LLC now owns 3,547,719 shares of the biopharmaceutical company’s stock valued at $124,170,000 after buying an additional 438,911 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Clovis Oncology by 294.2% in the fourth quarter. Millennium Management LLC now owns 1,173,873 shares of the biopharmaceutical company’s stock valued at $41,086,000 after buying an additional 876,068 shares in the last quarter. CLVS has been the subject of a number of other reports. Mizuho reduced their target price on shares of Clovis Oncology from $35.00 to $23.00 and set a neutral rating for the company in a research note on Monday, January 25th. JPMorgan Chase & Co. upped their target price on shares of Clovis Oncology from $103.00 to $110.00 and gave the stock an overweight rating in a research note on Friday, November 6th. Vetrraised shares of Clovis Oncology from a hold rating to a strong-buy rating and set a $54.87 target price for the company in a research note on Monday, November 16th. WallachBeth Capital lowered shares of Clovis Oncology from a buy rating to a hold rating and reduced their target price for the stock from $135.00 to $30.00 in a research note on Tuesday, November 17th. Finally,Zacks Investment Research lowered shares of Clovis Oncology from a hold rating to a sell rating in a research note on Friday, December 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $40.89. Clovis Oncology, Inc (NASDAQ:CLVS) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib.
C
COLOGNE79, 02.03.2016 22:12 Uhr
0
sieht chartmässig auf jedem Fall gut aus auch wenn sie nochnal etwas zurückkommt
V
VanHalen, 02.03.2016 22:03 Uhr
0
Wenn die 19,7x gepackt werden ist der nächste technische Widerstand bei 21,6x.. Und dann BAM!
Xdiculator
Xdiculator, 02.03.2016 21:54 Uhr
0
Es hat sich also gelohnt! http://250kb.de/u/160302/j/rg2pRlILhsAm.jpg
V
VanHalen, 02.03.2016 21:30 Uhr
0
Oh mein Gott... Anschnallen!!
V
VanHalen, 02.03.2016 21:22 Uhr
0
Besser so :-P
C
COLOGNE79, 02.03.2016 20:41 Uhr
0
ich sag jetzt nix; )
V
VanHalen, 02.03.2016 20:36 Uhr
0
Auf und nieder.. Immer wieder....
C
COLOGNE79, 02.03.2016 20:26 Uhr
0
weiss ich doch:)
V
VanHalen, 02.03.2016 20:13 Uhr
0
War doch nur ironisch/Spaß ;-)
C
COLOGNE79, 02.03.2016 20:12 Uhr
0
ruhig Blut...wir haben getestet. ..nach einem Test kommt???....richtig. ..erneuter Versuch ...geduldig sein.Ssge ich immer und immer wieder gern
V
VanHalen, 02.03.2016 20:07 Uhr
0
Maaaan xD hättest nix gesacht Cologne
Xdiculator
Xdiculator, 02.03.2016 20:01 Uhr
0
Mit Sicherheit! Nur wann?
C
COLOGNE79, 02.03.2016 19:58 Uhr
0
bald 40 usd? -;D
Mehr zu diesem Wert
Thema
1 CLOVIS ONCOLOGY Hauptdiskussion
2 Clovis Oncology -Informationen Austausch
Meistdiskutiert
Thema
1 Critical Infrastructure Technologies Hauptdiskussion -37,50 %
2 Trading- und Aktien-Chat
3 Novo Nordisk nach Split +3,66 %
4 INTEL Hauptdiskussion -1,06 %
5 Freunde der Tellekom +1,35 %
6 für alle, die es ehrlich meinen beim Traden.
7 PLUG POWER Hauptdiskussion ±0,00 %
8 Beyond Meat Hauptdiskussion +9,77 %
9 Security der nächsten Generation +8,64 %
10 ROHÖL BRENT Hauptdiskussion -0,50 %
Alle Diskussionen
Aktien
Thema
1 Critical Infrastructure Technologies Hauptdiskussion -37,50 %
2 Novo Nordisk nach Split +3,66 %
3 INTEL Hauptdiskussion -1,06 %
4 Freunde der Tellekom +1,35 %
5 PLUG POWER Hauptdiskussion ±0,00 %
6 Beyond Meat Hauptdiskussion +9,77 %
7 Security der nächsten Generation +8,64 %
8 Haffner Energy SAS Hauptdiskussion +18,48 %
9 APPLE Hauptdiskussion +3,45 %
10 Canopy Hauptforum +0,90 %
Alle Diskussionen